Membrane proteins as drug targets [electronic resource] / edited by Charles A. Lunn.
- Other Title:
- Membrane protiens [sic] as drug targets
- Amsterdam : Elsevier, 2010.
- Progress in molecular biology and translational science ; v. 91.
Progress in molecular biology and translational science, 1877-1173 ; v. 91
1 online resource (260 p.)
- Drug development.
- Electronic books.
- Membrane proteins continue to be prime drug targets because they perform essential processes in the cell including controlling the flow of information and materials between cells and mediating activities like hormone action and nerve impulses. The study of membrane proteins could lead to new and improved pharmaceutical treatments for a wide range of illnesses such as heart disease, cystic fibrosis and depression. This volume reviews the latest developments in the field. * Discusses new discoveries, approaches, and ideas in the field of membrane proteins and reviews how
- Front Cover; Progress in Molecular Biology and Translational Science; Copyright Page; Contents; Contributors; Preface; Chapter 1: Inverse Agonism at Serotonin and Cannabinoid Receptors; I. Serotonin Receptors; II. Constitutive Receptor Activity and Inverse Agonism; III. Ligands Identified In Vitro as Inverse Agonists at 5-HT Receptors; IV. Characteristics of Serotonin2A (5-HT2A) and 5-HT2C Receptors; V. Measurement of Constitutive Activity and Inverse Agonism In Vivo; VI. Inverse Agonism and Constitutive Activity of the Serotonin 5-HT2A Receptor In Vivo
VII. Inverse Agonism and Constitutive Activity of the Serotonin 5-HT2C Receptor In VivoVIII. Cannabinoid Receptors; IX. Summary; References; Chapter 2: G Protein-Coupled Receptor Heteromers as New Targets for Drug Development; I. Unique Biochemical Characteristics of GPCR Heteromers; II. Energy Transfer-Based Techniques to Study GPCR Oligomerization; III. Receptor Heteromers as Pharmacological Targets; Acknowledgments; References; Chapter 3: Receptor Activity Modifying Proteins and Their Potential as Drug Targets; I. Introduction; II. RAMPs and Their Discovery
III. RAMPs and Their Interaction with GPCRsIV. RAMP Modulation of GPCR Pharmacology; V. RAMPs as Receptor Chaperones; VI. RAMPs and Receptor Internalization; VII. RAMPs and Receptor Signaling; VIII. Posttranslational Modifications of RAMPs-Glycosylation; IX. Correlation of RAMPs with Receptors In Vivo; X. Regulation of RAMPs in Disease; XI. RAMPs as Drug Targets; XII. Concluding Remarks; References; Chapter 4: Regulators of G Protein Signaling Proteins as Targets for Drug Discovery; I. Introduction; II. RGS Protein Families; III. RGS Protein Mechanisms of Actions
IV. Biological Functions of RGS ProteinsV. Reaching Specificity-Modulating Specific Receptors and Signaling Pathways; VI. Targeting RGS Proteins in Drug Discovery-From Increased Knowledge to Increased Throughput; VII. Future Prospects; References; Chapter 5: Escorts Take the Lead: Molecular Chaperones as Therapeutic Targets; I. Introduction; II. Molecular Chaperones and Accessory Proteins; III. GPCR Maturation and Postendoplasmic Reticulum Trafficking; IV. Regulated Translocation to Intracellular Compartments and/or the Plasma Membrane; V. GPCR Oligomerization
VI. Specific Molecular Chaperones for GPCRsVII. The Melanocortin-2 Receptor and MRAP; VIII. Opioid Receptors and RTP4; IX. Pharmacological Chaperones; X. Conclusions; Acknowledgments; References; Chapter 6: The T1R2/T1R3 Sweet Receptor and TRPM5 Ion Channel: Taste Targets with Therapeutic Potential; I. Ingestive Behaviors as Therapeutic Endpoints; II. Taste Signaling Proteins as Targets for the Drug Discovery Approach; III. Obesity and Diabetes-The Result of Dysfunctional Ingestive Behavior; IV. The T1R2/T1R3 Sweet Receptor; V. The TRPM5 Ion Channel
VI. Morphological and Functional Characteristics of Type II Taste Cells
- Description based upon print version of record.
Includes bibliographical references and index.
- Lunn, Charles A.
|Location||Notes||Your Loan Policy|
|Description||Status||Barcode||Your Loan Policy|